DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy

Fertility and Sterility

Volumn 82, Issue 1, 2004, Pages 132-137

  Tempfer, Clemens B ^a,b   Riener, Eva Katrin ^a   Hefler, Lukas A ^b   Huber, Johannes C ^b   Muendlein, Axel ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hormone replacement therapy; microarray; polymorphism; risk assessment

Indexed keywords

ANGIOTENSINOGEN; APOLIPOPROTEIN E; AROMATASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ARTICLE; BONE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC RISK; HEART INFARCTION; HOMOZYGOTE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; METHODOLOGY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COUNSELING; PATIENT INFORMATION; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTECTION; PUNCTURE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; VEIN;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT;

EID: 3242744485     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.12.034     Document Type: Article

References (19)

1. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613
2. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 343:2000;522-529
3. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 288:2002;321-333
4. Psaty B.M., Smith N.L., Lemaitre R.N., Vos H.L., Heckbert S.R., LaCroix A.Z., et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA. 285:2001;906-913
5. Braunstein J.B., Kershner D.W., Bray P., Gerstenblith G., Schulman S.P., Post W.S., et al. Interaction of hemostatic genetics with hormone therapy new insights to explain arterial thrombosis in postmenopausal women. Chest. 121:2002;906-920
6. Thompson P.A., Shields P.G., Freudenheim J.L., Stone A., Vena J.E., Marshall J.R., et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res. 58:1998;2107-2110
7. Lavigne J.A., Helzlsouer K.J., Huang H.Y., Strickland P.T., Bell D.A., Selmin O., et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res. 57:1997;5493-5497
8. Miyoshi Y., Takahashi Y., Egawa C., Noguchi S. Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J. 8:2002;209-215
9. Ishibe N., Hankinson S.E., Colditz G.A., Spiegelman D., Willett W.C., Speizer F.E., et al. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res. 58:1998;667-671
10. Zheng W., Xie D.W., Jin F., Cheng J.R., Dai Q., Wen W.Q., et al. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 9:2000;147-150
11. Watanabe J., Shimada T., Gillam E.M., Ikuta T., Suemasu K., Higashi Y., et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics. 10:2000;25-33
12. Ambrosone C.B., Moysich K.B., Furberg H., Freudenheim J.L., Bowman E.D., Ahmed S., et al. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res. 5:2003;45-51
13. Feigelson H.S., Coetzee G.A., Kolonel L.N., Ross R.K., Henderson B.E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57:1997;1063-1065
14. Miyoshi Y., Iwao K., Ikeda N., Egawa C., Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer. 89:2000;325-328
15. Kristensen V.N., Harada N., Yoshimura N., Haraldsen E., Lonning P.E., Erikstein B., et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 19:2000;1329-1333
16. Deng H.W., Li J., Li J.L., Johnson M., Gong G., Recker R.R. Association of VDR and estrogen receptor genotypes with bone mass in postmenopausal Caucasian women different conclusions with different analyses and the implications. Osteoporos Int. 9:1999;499-507
17. Salmen T., Heikkinen A.M., Mahonen A., Kroger H., Komulainen M., Saarikoski S., et al. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women. J Bone Miner Res. 15:2000;2479-2486
18. Huber M., Muendlein A., Dornstauder E., Schneeberger C., Tempfer C.B., Mueller M.W., et al. Accessing single nucleotide polymorphisms in genomic DNA by direct multiplex polymerase chain reaction amplification on oligonucleotide microarrays. Anal Biochem. 30:2002;25-33
19. Herrington D.M., Howard T.D., Hawkins G.A., Reboussin D.M., Xu J., Zheng S.L., et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 346:2002;967-974